Hospital Targeting Valtari Bio’s rapid point-of-care stroke triage test is designed for hospital EDs and stroke programs, offering a fast decision aid to differentiate ischemic, hemorrhagic stroke and TIA from mimics. This creates a compelling sales angle for hospital procurement teams, stroke program directors, and ED leadership seeking to shorten door-to-treatment times and improve triage accuracy.

EMS Collaboration There is potential to partner with EMS providers and mobile clinics to deploy the test in pre-hospital settings or enable pre-notification to receiving hospitals, accelerating stroke pathway activation and potentially improving patient outcomes. Such collaborations can unlock new channels with EMS agencies and hospital networks seeking end-to-end workflow improvements.

Regulatory Pathway Because the product is a point-of-care diagnostic, pursuing regulatory clearance and multi-site clinical validation would be critical to unlock hospital adoption, establish clinician trust, and support payer conversations around reimbursement.

Partnership Channels With a small team, Valtari Bio can monetize through distribution agreements with established medical device and diagnostic distributors, and pursue integration with hospital IT and EHR workflows, enabling faster scaling through existing channels and partner ecosystems.

Market Positioning The value proposition centers on rapid on-site triage to reduce misdiagnosis, imaging overuse, and treatment delays. Positioning the test as a workflow-enhancing tool for ED and stroke programs, backed by pilot results and ROI case studies, can drive faster adoption and budget approvals.